UNSPSC 51182410: Etidronate

This classification denotes a bone resorption inhibitor and biphosphonate with the molecular formula C2H6O7P2.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M16PXG993G, chemically known as 1,1,1-ethanetriol diphosphonate but generally known as etidronate disodium, which bears US NIH Compound Identifier 3305. European Medicines Agency schedules Etidronate disodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13771MIG. SMILES: P(=O)(O)(O)C(P(=O)(O)O)(O)C.

UNSPSC 51182410 Etidronate, a Commodity code, covers pharmaceutical products supplied to state and local government entities through cooperative purchasing agreements and direct vendor contracts. State and local governments procure etidronate—a bisphosphonate used to treat osteoporosis and related bone conditions—as part of broader pharmaceutical inventory contracts that bundle generic multi-source drugs and over-the-counter products. These procurements are typically issued by state purchasing offices, cooperative purchasing alliances, and healthcare facilities within state and local systems. The work involves manufacturers or authorized wholesalers providing pharmaceutical products meeting FDA cGMP and Drug Supply Chain Security Act (DSCSA) compliance standards, with pricing structured through established pharmaceutical distribution channels and chargeback systems to ensure consistent supply and cost control across participating jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued the primary recent opportunity on this code—a Request for Proposal (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, with responses due March 26, 2026. The procurement extends to participating state and local government facilities across MMCAP's member states, including Oregon. Vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), hold $5 million commercial general liability coverage and $2 million network security and professional liability coverage, and provide pricing in flat, net, or WAC-minus formats. Evaluation emphasizes price competitiveness (75 percent), with the remaining weight on fixed pricing, administrative fee compliance, EDI capability, and the 3 percent administrative fee obligation. The contract term spans two years for new awardees with optional extensions, while incumbent responders' amendments extend through June 30, 2028.